SH3GL2

Across TCGA pan-cancer cohorts, SH3GL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH3GL2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SH3GL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH3GL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, ESCA, and LIHC are the cancer types where SH3GL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.122	0.680	.004	21	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	15	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	3	view →
LUAD	OS	Median	III,IV	1.000	0.274	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH3GL2–HNSC (DFS)

Open the HNSC breakdown →